The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1686
ISSUE 1686
October 2, 2023
Issue 1686
- Two Vaccines (Arexvy and Abrysvo) for Prevention of RSV Disease
- Lodoco: Low-Dose Colchicine for Cardiovascular Event Prevention
- Valoctocogene Roxaparvovec (Roctavian) – A Gene Therapy for Severe Hemophilia A
- Delandistrogene Moxeparvovec (Elevidys) for Duchenne Muscular Dystrophy
- Addendum: Gabapentinoids and Renal Impairment
- Addendum: Over-the-Counter Narcan Nasal Spray
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Two Vaccines (Arexvy and Abrysvo) for Prevention of RSV Disease
October 2, 2023 (Issue: 1686)
Two recombinant vaccines, Arexvy (GSK) and
Abrysvo (Pfizer), have been approved by the FDA for
prevention of lower respiratory tract disease (LRTD)
caused by respiratory syncytial virus (RSV) in adults
≥60 years old. They are the first RSV...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.